Application of Drug Repositioning Strategy to TOFISOPAM
Authors: Bernard, P.; Dufresne-Favetta, C.; Favetta, P.; Do, Q.-T.; Himbert, F.; Zubrzycki, S.; Scior, T.; Lugnier, C.
Source: Current Medicinal Chemistry, Volume 15, Number 30, December 2008 , pp. 3196-3203(8)
Publisher: Bentham Science Publishers
Abstract:Drug repositioning strategy is an interesting approach for pharmaceutical companies ; especially to increase their productivity. SELNERGYtm, is a reverse docking based-program able to virtually screen thousands of compounds on more than 2000 3D biological targets. This program was successfully applied to tofisopam and revealed that the isomers of tofisopam are able to fit with phosphodiesterase 4. This old drug was used as a racemic mixture to treat anxiety in the eighties and was recently shown to act as a PDE4 inhibitor. Thanks to this strategy we demonstrated that tofisopam acts via the inhibition of PDE4 in the submicromolar range. Moreover, we firstly showed that the S-enantiomer of tofisopam is ten times more active than R-enantiomer. The identification of the biochemical mechanism of tofisopam isomers now allows to reposition this drug in new therapeutic indications where modulation of cAMP via PDE4 inhibitors are possible.
Document Type: Research article
Publication date: 2008-12-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.